KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Net Income (2019 - 2025)

Historic Net Income for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $444.2 million.

  • Royalty Pharma's Net Income fell 4491.14% to $444.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 2400.27%. This contributed to the annual value of $1.3 billion for FY2024, which is 2172.09% down from last year.
  • Per Royalty Pharma's latest filing, its Net Income stood at $444.2 million for Q3 2025, which was down 4491.14% from $90.6 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Net Income ranged from a high of $806.8 million in Q2 2021 and a low of -$610.0 million during Q4 2022
  • For the 5-year period, Royalty Pharma's Net Income averaged around $287.9 million, with its median value being $221.8 million (2021).
  • Per our database at Business Quant, Royalty Pharma's Net Income crashed by 123661.01% in 2022 and then skyrocketed by 1024352.91% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Net Income stood at $53.7 million in 2021, then tumbled by 1236.61% to -$610.0 million in 2022, then surged by 217.63% to $717.6 million in 2023, then plummeted by 53.41% to $334.4 million in 2024, then surged by 32.86% to $444.2 million in 2025.
  • Its Net Income stands at $444.2 million for Q3 2025, versus $90.6 million for Q2 2025 and $433.4 million for Q1 2025.